NCT02225639View on ClinicalTrials.gov

PRC-063 in an ADULT Workplace Environment

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

May 31, 2015

Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
DRUG

PRC-063 25 mg

Oral 25 mg capsule - active

DRUG

Placebo

Oral placebo capsule

DRUG

PRC-063 35 mg

Oral 35 mg capsule - active

DRUG

PRC-063 45 mg

Oral 45 mg capsule - active

DRUG

PRC-063 55 mg

Oral 55 mg capsule - active

DRUG

PRC-063 70 mg

Oral 70 mg capsule - active

DRUG

PRC-063 85 mg

Oral 85 mg capsule - active

DRUG

PRC-063 100 mg

Oral 100 mg capsule - active

Trial Locations (2)

89128

Center for Psychiatry and Behavioral Medicine Inc., Las Vegas

92660

AVIDA, Inc., Newport Beach

All Listed Sponsors
collaborator

Purdue Pharma LP

INDUSTRY

lead

Rhodes Pharmaceuticals, L.P.

INDUSTRY

NCT02225639 - PRC-063 in an ADULT Workplace Environment | Biotech Hunter | Biotech Hunter